Medicine Management Flashcards
Pre-clinical testing procedures of a new drug
Mechanism of action
Efficacy
Toxicity studies (LD50)
Carcinogenicity (if drug can cause cancer or damages DNA)
Teratogenicity (testing abnormalities in the foetus) - normally tested to lab animals such as fruit flies and rodents
Phase 1 and 2 of clinical trials
- Human safety test by healthy volunteers (few pts) - last days or weeks
- Expanded safety test by healthy volunteers (hundreds) - last weeks or months
Phase 3 of clinical trials
- Efficacy and safety (thousands of volunteers) - last several years
Gold standard - randomised, double blind, comparison with placebo and not industry sponsored (publication bias)
Trial cessation - if evidence of harm was observed and no evidence of benefit
A drug with no active agents used for clinical trials
Placebo
Phase 4 of clinical trials
- studies side effects caused over time by a new treatment after it has been approved and is on the market.
Who can prescribe medicine according to NZ legislation in Medicines Act
Authorised prescriber (nurse practitioner, optometrist, registered midwife) Practitioner (medical practitioners) Designated prescriber (registered health professionals) Standing orders (written instruction from health services)
List the schedules in the Medicines Regulations of NZ legislation
Prescription
Restricted or pharmacist only
Pharmacy only meds
General sale meds
Classification of drugs according to NZ legislation in Misuse of Drugs Act (Classification of drugs section 3a)
Class A - drugs that pose a very high risk of harm (cocaine)
Class B - drugs that pose a high risk of harm (oxycodone) - opioids
Class C - drugs that pose a moderate risk of harm (benzodiazepines, codeine)
the use of multiple medicines which is common for older population with multi morbidity
Polypharmacy